journal article·2026-05Open access

Exploiting anti-mitotic therapy as a cell cycle-responsive strategy to enhance nano-agent retention in tumor cells

Feifan Zhao, Jinglin Wu, Xinyuan Li, Bowen Zhang, Wei Zhang, Jin Li, Yan Liu

Cell Reports Physical Science· Volume 7· Issue 5

Abstract

Rapidly proliferating cancer cells can quickly dilute internalized nano-agents. It is necessary to devise strategies to decelerate the nano-agent dilution ensuing from cell division. Here, we propose a sequential strategy involving cell cycle-responsive therapy (radiation therapy [RT] or other anti-mitotic treatments) followed by nano-agent administration. Using diverse tumor cell lines, we evaluate the impact of cyclin-dependent kinase (CDK) inhibitors, paclitaxel, and X-ray irradiation on cell cycle progression and subsequent polystyrene nanoparticle retention. In vivo experiments further validate these findings. Moreover, our results demonstrate that a single pre-irradiation RT markedly decelerates liposomal doxorubicin dilution, thereby improving therapeutic outcomes. Our proof-of-concept work integrates statistical physics modeling, cellular experiments, and in vivo validation into a coherent, multi-scale framework and suggests that combined therapies integrating anti-mitotic strategies can optimize nano-agent delivery, enhancing therapeutic efficacy in clinical settings, thereby offering a universally applicable and clinically feasible strategy to overcome intrinsic drug resistance in rapidly proliferating tumors.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Microtubule and mitosis dynamics · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (50)

Show source-provided references
1. Precision Medicine: From Science To Value10.1377/hlthaff.2017.1624 ↗
2. Review of precision cancer medicine: Evolution of the treatment paradigm10.1016/j.ctrv.2020.102019 ↗
3. Human Absorption, Distribution, Metabolism, and Excretion Studies: Origins, Innovations, and Importance10.1124/dmd.122.001006 ↗
4. The EPR Effect and Beyond: Strategies to Improve Tumor Targeting and Cancer Nanomedicine Treatment Efficacy10.7150/thno.49577 ↗
5. Targeted drug delivery strategies for precision medicines10.1038/s41578-020-00269-6 ↗
6. Targeting Strategies for Tissue-Specific Drug Delivery10.1016/j.cell.2020.02.001 ↗
7. Endosomal escape pathways for delivery of biologicals10.1016/j.jconrel.2010.11.004 ↗
8. Intracellular Protein Delivery: Approaches, Challenges, and Clinical Applications10.34133/bmef.0035 ↗
9. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population10.1038/nnano.2011.191 ↗
10. Cytosolic Delivery of Nanolabels Prevents Their Asymmetric Inheritance and Enables Extended Quantitative in Vivo Cell Imaging10.1021/acs.nanolett.6b01411 ↗
11. Intracellular delivery of colloids: Past and future contributions from microinjection10.1016/j.addr.2018.06.013 ↗
12. Reduction of Nanoparticle Load in Cells by Mitosis but Not Exocytosis10.1021/acsnano.9b01604 ↗
13. Metal fluoride nanoregulators reverse therapeutic resistance via stemness remodeling to trigger pyroptosis for chemoimmunotherapy
14. Cell cycle control in cancer10.1038/s41580-021-00404-3 ↗
15. Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity10.1016/j.cell.2023.05.013 ↗
16. The control of DNA repair by the cell cycle10.1038/ncb3452 ↗
17. Role of cell cycle in mediating sensitivity to radiotherapy10.1016/j.ijrobp.2004.03.005 ↗
18. Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer10.1038/s41571-021-00579-w ↗
19. Microtubules as a target for anticancer drugs10.1038/nrc1317 ↗
20. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death
21. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest10.1074/jbc.M310947200 ↗
22. Reply to 'The interface of nanoparticles with proliferating mammalian cells'10.1038/nnano.2017.139 ↗
23. DNA Damage-Inducing Anticancer Therapies: From Global to Precision Damage10.3390/cancers12082098 ↗
24. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK110.1073/pnas.0600447103 ↗
25. Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection10.1111/jphp.12257 ↗
26. A protease-cleavable liposome for co-delivery of anti-PD-L1 and doxorubicin for colon cancer therapy in mice10.1038/s41467-025-57965-6 ↗
27. Endocytosis at the nanoscale10.1039/c2cs15309b ↗
28. Endocytosis and exocytosis of nanoparticles in mammalian cells
29. Endocytosis Mechanism of Nano Metal-Organic Frameworks for Drug Delivery10.1002/adhm.201600296 ↗
30. Brief update on endocytosis of nanomedicines10.1016/j.addr.2019.08.004 ↗
31. Particles on the move: intracellular trafficking and asymmetric mitotic partitioning of nanoporous polymer particles10.1021/nn401800u ↗
32. Effect of the surface modification, size, and shape on cellular uptake of nanoparticles10.1002/cbin.10459 ↗
33. Cellular Uptake of Nanoparticles versus Small Molecules: A Matter of Size10.1021/acs.accounts.8b00292 ↗
34. CM-Dil Staining and SEC of Plasma as an Approach to Increase Sensitivity of Extracellular Nanovesicles Quantification by Bead-Assisted Flow Cytometry10.3390/membranes11070526 ↗
35. Thermodynamically controlled multiphase separation of heterogeneous liquid crystal colloids10.1038/s41467-023-41054-7 ↗
36. Nanoparticle Interactions with Living Systems: In Vivo and In Vitro Biocompatibility
37. Combination of chemotherapy and radiotherapy: A thirty years evolution10.1016/j.canrad.2019.07.157 ↗
38. Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers10.1158/1078-0432.CCR-20-2269 ↗
39. Causes and Consequences of Aneuploidy in Cancer10.1038/nrg3123 ↗
40. Effects of aneuploidy on cell behaviour and function10.1038/s41580-021-00436-9 ↗
41. Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition10.1038/s41586-020-03114-6 ↗
42. Reversible and Effective Cell Cycle Synchronization Method for Studying Stage-Specific Processes10.26508/lsa.202403000 ↗
43. Cell cycle synchronization at the G2/M phase border by reversible inhibition of CDK110.4161/cc.5.22.3463 ↗
44. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib10.1007/s10549-017-4385-3 ↗
45. CDK4/6 inhibitors induce replication stress to cause long-term cell cycle withdrawal10.15252/embj.2021108599 ↗
46. Radiation-induced Adaptive Response: New Potential for Cancer Treatment10.1158/1078-0432.CCR-20-0572 ↗
47. Targeting DNA damage response pathways in cancer10.1038/s41568-022-00535-5 ↗
48. A change of strategy in the war on cancer10.1038/459508a ↗
49. A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation10.7554/eLife.84263 ↗
50. High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review10.1016/j.ctrv.2021.102171 ↗